化学療法誘発性貧血の世界市場レポート 2025年

化学療法誘発性貧血市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.9％で38億1,000万米ドルに成長します。予測期間の成長は、がん治療における支持療法の開発、ヘルスケア支出とインフラの増加、個別化医療と標的がん治療、バイオマーカー主導型治療アプローチの統合、早期発見と介入への注目の高まり、患者管理におけるデジタルヘルス技術の統合などに起因すると考えられます。予測期間の主な動向には、新規化学療法剤の革新、mlの統合、がん研究と治療プロトコルの進歩、aiの統合、製薬会社と医療提供者の連携などがあります。

化学療法誘発性貧血市場の予測成長は、がんと貧血の高い有病率によって推進されると予想されます。制御不能な細胞増殖と体内他部位への転移を特徴とするがんは、放射線療法の有無にかかわらず、積極的な化学療法を受けている患者においてしばしば化学療法誘発性貧血（CIA）を引き起こします。化学療法誘発性貧血に対処するために、骨髄での赤血球産生を刺激するように設計された薬が一般的に使用されています。例えば、英国がん研究協会（Cancer Research UK）は、2023年から2025年にかけて英国における頭頸部がんの罹患率が3％増加し、同期間中に頭頸部がんによる死亡が12％増加すると予測しています。その結果、がんと貧血の有病率の上昇が化学療法誘発性貧血市場の成長に寄与しています。

研究開発費の増加が今後の化学療法誘発性貧血市場の成長を牽引すると予想されます。研究開発投資とは、企業が製品を開発、設計、強化するために発生する費用を指します。研究開発投資の増加は、化学療法誘発性貧血を治療するための新薬の創製や処方における技術革新と生産性を促進することができます。例えば、2024年4月、英国政府統計局は、英国政府の研究開発に対する純支出（EU拠出金を除く）が2022年には155億ポンド（193億7,500万米ドル）に上り、2021年の140億ポンド（175億米ドル）から10.5％増加したと報告しました。さらに、EUからの拠出金と知識移転活動を含む研究開発への純支出は、2022年には164億ポンド（205億米ドル）に達し、2021年の150億ポンド（187億5,000万米ドル）から8.9%増加しました。したがって、研究開発費の増加が化学療法誘発性貧血市場を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界化学療法誘発性貧血PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の化学療法誘発性貧血市場：成長率分析
• 世界の化学療法誘発性貧血市場の実績：規模と成長, 2019-2024
• 世界の化学療法誘発性貧血市場の予測：規模と成長, 2024-2029, 2034F
• 世界化学療法誘発性貧血総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の化学療法誘発性貧血市場貧血による、実績と予測, 2019-2024, 2024-2029F, 2034F
• 軽度の貧血
• 中等度の貧血
• 重度の貧血
• 生命を脅かす貧血
• 世界の化学療法誘発性貧血市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 赤血球輸血
• 赤血球造血刺激因子（ESA）
• 鉄分補給
• 世界の化学療法誘発性貧血市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 外来手術センター
• 多科クリニック
• がん研究センター
• がんリハビリテーションセンター
• 世界の化学療法誘発性貧血市場軽度貧血のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヘモグロビン値 10～12 g/dL
• 対症療法
• 世界の化学療法誘発性貧血市場中等度貧血のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヘモグロビン値 8～10 g/dL
• 赤血球生成刺激因子（ESA）
• 輸血管理
• 世界の化学療法誘発性貧血市場重症貧血の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヘモグロビン値 6.5～8 g/dL
• 集中ESA治療
• 頻繁な輸血
• 世界の化学療法誘発性貧血市場生命を脅かす貧血の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヘモグロビン濃度 6.5 g/dL未満
• 緊急介入
• 集中治療とモニタリング

第7章 地域別・国別分析

• 世界の化学療法誘発性貧血市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の化学療法誘発性貧血市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 化学療法誘発性貧血市場：競合情勢
• 化学療法誘発性貧血市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sanofi S.A.
• Bristol-Myers Squibb Company
• AstraZeneca plc
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Boehringer Ingelheim International GmbH
• Amgen Inc.
• Baxter International Inc.
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Astellas Pharma Inc.
• Fresenius Kabi AG
• Hospira Inc.
• Dr. Reddy's Laboratories Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 化学療法誘発性貧血市場2029：新たな機会を提供する国
• 化学療法誘発性貧血市場2029：新たな機会を提供するセグメント
• 化学療法誘発性貧血市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Chemotherapy-Induced Anemia is a decrease in red blood cells resulting from chemotherapy treatments, which can lead to symptoms such as fatigue and weakness. Managing this condition is essential for improving patients' quality of life during cancer treatment. Treatment often involves erythropoiesis-stimulating agents or blood transfusions to help alleviate the symptoms and restore red blood cell levels.

The various categories of chemotherapy-induced anemia include mild, moderate, severe, and life-threatening anemia. Mild anemia denotes a condition where an individual has hemoglobin levels below the standard range. Treatment protocols, including red blood cell (RBC) transfusion, erythropoiesis-stimulating agents (ESAs), and iron supplementation, are applicable in diverse end-user settings such as hospitals, ambulatory surgical centers, multispecialty clinics, cancer research centers, and cancer rehabilitation centers.

The chemotherapy-induced anemia report is one of a series of new reports from The Business Research Company that provides chemotherapy-induced anemia market statistics, including the chemotherapy-induced anemia industry's global market size, regional shares, competitors with chemotherapy-induced anemia market share, detailed chemotherapy-induced anemia market segments, market trends, and opportunities, and any further data you may need to thrive in the chemotherapy-induced anemia industry. This chemotherapy-induced anemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chemotherapy-induced anemia market size has grown strongly in recent years. It will grow from $2.62 billion in 2024 to $2.82 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to increased prevalence of cancer and chemotherapy treatments, aging population leading to higher cancer incidence, expansion of chemotherapy drugs and regimens, improvement in overall cancer survival rates, awareness and diagnosis of anemia as a side effect

The chemotherapy-induced anemia market size is expected to see strong growth in the next few years. It will grow to $3.81 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to development of supportive care in oncology, rise in healthcare expenditure and infrastructure, personalized medicine and targeted cancer therapies, integration of biomarker-driven treatment approaches, increasing focus on early detection and intervention, integration of digital health technologies in patient management. Major trends in the forecast period include innovation of novel chemotherapy agents, integration of ml, advancements in cancer research and treatment protocols, integration of ai, collaboration between pharmaceutical companies and healthcare providers.

The anticipated growth in the chemotherapy-induced anemia market is expected to be propelled by the high prevalence of cancer and anemia. Cancer, characterized by uncontrolled cell growth and spreading to other parts of the body, often leads to chemotherapy-induced anemia (CIA) in patients undergoing aggressive chemotherapy, with or without radiation therapy. Medications designed to stimulate red blood cell production in the bone marrow are commonly used to address chemotherapy-induced anemia. For instance, Cancer Research UK projects a 3% increase in the incidence of head and neck cancer in the UK from 2023 to 2025, with a corresponding 12% rise in deaths due to head and neck cancers during the same period. Consequently, the elevated prevalence of cancer and anemia contributes to the growth of the chemotherapy-induced anemia market.

The increase in research and development expenditure is expected to drive the growth of the chemotherapy-induced anemia market in the future. Research and development investment refers to the expenses incurred by a company to develop, design, and enhance its products. Higher R&D spending can foster innovation and productivity in creating and formulating new drugs to treat chemotherapy-induced anemia. For instance, in April 2024, the Office for National Statistics, a UK government department, reported that the UK government's net expenditure on research and development (excluding EU contributions) rose to £15.5 billion ($19.375 billion) in 2022, marking a 10.5% increase from £14.0 billion ($17.5 billion) in 2021. Furthermore, total net expenditure on R&D, including EU contributions and knowledge transfer activities, reached £16.4 billion ($20.5 billion) in 2022, reflecting an 8.9% rise from £15.0 billion ($18.75 billion) in 2021. Therefore, the rising R&D expenditure is driving the chemotherapy-induced anemia market forward.

Major companies in the chemotherapy-induced anemia market are focusing on developing innovative products, such as biosimilars, to enhance treatment efficacy and reduce costs. Biosimilars are biologic medical products that closely resemble an already approved reference biologic drug, showing no significant differences in safety, purity, or effectiveness. They provide more affordable alternatives to expensive biologic treatments while maintaining similar therapeutic outcomes. For example, in November 2022, Amneal Pharmaceuticals, Inc., a US-based pharmaceutical company, launched RELEUKO (filgrastim-ayow), which references Neupogen(R). This product is primarily indicated for treating neutropenia, a common condition among chemotherapy patients. RELEUKO offers significant benefits for cancer treatment by reducing the incidence of infections related to febrile neutropenia in patients receiving myelosuppressive chemotherapy, thereby enhancing safety and recovery. Additionally, RELEUKO aids in shortening the time to neutrophil recovery and reduces the duration of fever following chemotherapy for acute myeloid leukemia, helping to mitigate the complications of neutropenia in patients undergoing bone marrow transplantation.

Major companies in the chemotherapy-induced anemia market are focusing on developing technological advancements, such as Ojjaara (momelotinib), to enhance treatment options and improve patient outcomes for those affected by anemia related to cancer therapies. The name "Ojjaara" is inspired by the word "Ojaara," reflecting a connection to healing and wellness. For instance, in September 2023, Ojjaara (momelotinib) was developed by GSK (GlaxoSmithKline), a UK-based company. This drug represents a significant advancement in the treatment of myelofibrosis, particularly for patients with anemia. Ojjaara works by inhibiting key pathways to improve blood counts, enhance quality of life, and reduce the need for blood transfusions, making it the first and only therapy specifically indicated for this condition.

In August 2022, CSL Limited, an Australia-based biotechnology company, acquired Vifor Pharma AG for an undisclosed amount. This strategic acquisition aimed to diversify CSL's business by integrating Vifor's franchises, thereby strengthening CSL's position in a high-growth and less competitive sector. Vifor Pharma AG is a Switzerland-based pharmaceutical company with a pipeline of drugs for chemotherapy-induced anemia.

Major companies operating in the chemotherapy-induced anemia market include Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Fresenius Kabi AG, Hospira Inc., Dr. Reddy's Laboratories Ltd., Biocon Ltd., 3SBio Group, FibroGen Inc., Karger AG, Avesthagen Ltd., Blausen Medical Communications Inc., Aileron Therapeutics Inc.

North America was the largest region in the chemotherapy-induced anemia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chemotherapy-induced anemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the chemotherapy-induced anemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The chemotherapy-induced anemia market consists of sales of androxy oral, epoetin alfa injection, epogen injection, procrit injection, and aranesp injection. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chemotherapy-Induced Anemia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chemotherapy-induced anemia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chemotherapy-induced anemia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chemotherapy-induced anemia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Anemia: Mild Anemia; Moderate Anemia; Severe Anemia; Life-Threatening Anemia
• 2) By Treatment Type: RBC (Red Blood Cells) Transfusion; Erythropoiesis-Stimulating Agents (ESAs); Iron Supplementation
• 3) By End-User: Hospitals; Ambulatory Surgical Centers; Multispecialty Clinics; Cancer Research Centers; Cancer Rehabilitation Centers
• Subsegments:
• 1) By Mild Anemia: Hemoglobin Levels 10-12 g/dL; Symptomatic Treatments
• 2) By Moderate Anemia: Hemoglobin Levels 8-10 g/dL; Erythropoiesis-stimulating Agents (ESAs); Blood Transfusion Management
• 3) By Severe Anemia: Hemoglobin Levels 6.5-8 g/dL; Intensive ESA Treatments; Frequent Blood Transfusions
• 4) By Life-Threatening Anemia: Hemoglobin Levels Below 6.5 g/dL; Emergency interventions; Critical Care And Monitoring
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Chemotherapy-Induced Anemia Market Characteristics

3. Chemotherapy-Induced Anemia Market Trends And Strategies

4. Chemotherapy-Induced Anemia Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Chemotherapy-Induced Anemia Growth Analysis And Strategic Analysis Framework

• 5.1. Global Chemotherapy-Induced Anemia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Chemotherapy-Induced Anemia Market Growth Rate Analysis
• 5.4. Global Chemotherapy-Induced Anemia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Chemotherapy-Induced Anemia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Chemotherapy-Induced Anemia Total Addressable Market (TAM)

6. Chemotherapy-Induced Anemia Market Segmentation

• 6.1. Global Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mild Anemia
• Moderate Anemia
• Severe Anemia
• Life-Threatening Anemia
• 6.2. Global Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• RBC (Red Blood Cells) Transfusion
• Erythropoiesis-Stimulating Agents (ESAs)
• Iron Supplementation
• 6.3. Global Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Ambulatory Surgical Centers
• Multispecialty Clinics
• Cancer Research Centers
• Cancer Rehabilitation Centers
• 6.4. Global Chemotherapy-Induced Anemia Market, Sub-Segmentation Of Mild Anemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hemoglobin Levels 10-12 g/dL
• Symptomatic Treatments
• 6.5. Global Chemotherapy-Induced Anemia Market, Sub-Segmentation Of Moderate Anemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hemoglobin Levels 8-10 g/dL
• Erythropoiesis-stimulating Agents (ESAs)
• Blood Transfusion Management
• 6.6. Global Chemotherapy-Induced Anemia Market, Sub-Segmentation Of Severe Anemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hemoglobin Levels 6.5-8 g/dL
• Intensive ESA Treatments
• Frequent Blood Transfusions
• 6.7. Global Chemotherapy-Induced Anemia Market, Sub-Segmentation Of Life-Threatening Anemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hemoglobin Levels Below 6.5 g/dL
• Emergency interventions
• Critical Care And Monitoring

7. Chemotherapy-Induced Anemia Market Regional And Country Analysis

• 7.1. Global Chemotherapy-Induced Anemia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Chemotherapy-Induced Anemia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Chemotherapy-Induced Anemia Market

• 8.1. Asia-Pacific Chemotherapy-Induced Anemia Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Chemotherapy-Induced Anemia Market

• 9.1. China Chemotherapy-Induced Anemia Market Overview
• 9.2. China Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Chemotherapy-Induced Anemia Market

• 10.1. India Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Chemotherapy-Induced Anemia Market

• 11.1. Japan Chemotherapy-Induced Anemia Market Overview
• 11.2. Japan Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Chemotherapy-Induced Anemia Market

• 12.1. Australia Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Chemotherapy-Induced Anemia Market

• 13.1. Indonesia Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Chemotherapy-Induced Anemia Market

• 14.1. South Korea Chemotherapy-Induced Anemia Market Overview
• 14.2. South Korea Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Chemotherapy-Induced Anemia Market

• 15.1. Western Europe Chemotherapy-Induced Anemia Market Overview
• 15.2. Western Europe Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Chemotherapy-Induced Anemia Market

• 16.1. UK Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Chemotherapy-Induced Anemia Market

• 17.1. Germany Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Chemotherapy-Induced Anemia Market

• 18.1. France Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Chemotherapy-Induced Anemia Market

• 19.1. Italy Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Chemotherapy-Induced Anemia Market

• 20.1. Spain Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Chemotherapy-Induced Anemia Market

• 21.1. Eastern Europe Chemotherapy-Induced Anemia Market Overview
• 21.2. Eastern Europe Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Chemotherapy-Induced Anemia Market

• 22.1. Russia Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Chemotherapy-Induced Anemia Market

• 23.1. North America Chemotherapy-Induced Anemia Market Overview
• 23.2. North America Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Chemotherapy-Induced Anemia Market

• 24.1. USA Chemotherapy-Induced Anemia Market Overview
• 24.2. USA Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Chemotherapy-Induced Anemia Market

• 25.1. Canada Chemotherapy-Induced Anemia Market Overview
• 25.2. Canada Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Chemotherapy-Induced Anemia Market

• 26.1. South America Chemotherapy-Induced Anemia Market Overview
• 26.2. South America Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Chemotherapy-Induced Anemia Market

• 27.1. Brazil Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Chemotherapy-Induced Anemia Market

• 28.1. Middle East Chemotherapy-Induced Anemia Market Overview
• 28.2. Middle East Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Chemotherapy-Induced Anemia Market

• 29.1. Africa Chemotherapy-Induced Anemia Market Overview
• 29.2. Africa Chemotherapy-Induced Anemia Market, Segmentation By Anemia, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Chemotherapy-Induced Anemia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Chemotherapy-Induced Anemia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Chemotherapy-Induced Anemia Market Competitive Landscape And Company Profiles

• 30.1. Chemotherapy-Induced Anemia Market Competitive Landscape
• 30.2. Chemotherapy-Induced Anemia Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Chemotherapy-Induced Anemia Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. Bristol-Myers Squibb Company
• 31.3. AstraZeneca plc
• 31.4. GlaxoSmithKline plc
• 31.5. Takeda Pharmaceutical Company Limited
• 31.6. Eli Lilly and Company
• 31.7. Boehringer Ingelheim International GmbH
• 31.8. Amgen Inc.
• 31.9. Baxter International Inc.
• 31.10. Teva Pharmaceutical Industries Ltd.
• 31.11. Mylan N.V.
• 31.12. Astellas Pharma Inc.
• 31.13. Fresenius Kabi AG
• 31.14. Hospira Inc.
• 31.15. Dr. Reddy's Laboratories Ltd.

32. Global Chemotherapy-Induced Anemia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chemotherapy-Induced Anemia Market

34. Recent Developments In The Chemotherapy-Induced Anemia Market

35. Chemotherapy-Induced Anemia Market High Potential Countries, Segments and Strategies

• 35.1 Chemotherapy-Induced Anemia Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Chemotherapy-Induced Anemia Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Chemotherapy-Induced Anemia Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer